These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 4028627)

  • 1. Controlled trial of acifran in type II hyperlipoproteinemia.
    Hunninghake DB; Edwards KD; Sopko GS; Tosiello RL
    Clin Pharmacol Ther; 1985 Sep; 38(3):313-7. PubMed ID: 4028627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acifran: a double-blind, randomized, placebo-controlled efficacy study in type IIa hyperlipoproteinemic patients.
    LaRosa JC; Miller VT; Edwards KD; DeBovis MR; Stoy DB
    Artery; 1987; 14(6):338-50. PubMed ID: 3314798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neomycin and plasma lipoproteins in type II hyperlipoproteinemia.
    Hoeg JM; Schaefer EJ; Romano CA; Bou E; Pikus AM; Zech LA; Bailey KR; Gregg RE; Wilson PW; Sprecher DL
    Clin Pharmacol Ther; 1984 Oct; 36(4):555-65. PubMed ID: 6383687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
    Thomas GS; Cromwell WC; Ali S; Chin W; Flaim JD; Davidson M
    J Am Coll Cardiol; 2013 Dec; 62(23):2178-84. PubMed ID: 24013058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normalization of plasma lipoprotein concentrations in patients with type II hyperlipoproteinemia by combined use of neomycin and niacin.
    Hoeg JM; Maher MB; Bou E; Zech LA; Bailey KR; Gregg RE; Sprecher DL; Susser JK; Pikus AM; Brewer HB
    Circulation; 1984 Dec; 70(6):1004-11. PubMed ID: 6388897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia.
    Akdim F; Visser ME; Tribble DL; Baker BF; Stroes ES; Yu R; Flaim JD; Su J; Stein EA; Kastelein JJ
    Am J Cardiol; 2010 May; 105(10):1413-9. PubMed ID: 20451687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment.
    Pons P; Rodríguez M; Robaina C; Illnait J; Más R; Fernández L; Fernández JC
    Int J Clin Pharmacol Res; 1994; 14(1):27-33. PubMed ID: 7927958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74.
    Mahboubi K; Witman-Jones T; Adamus JE; Letsinger JT; Whitehouse D; Moorman AR; Sawicki D; Bergenhem N; Ross SA
    Biochem Biophys Res Commun; 2006 Feb; 340(2):482-90. PubMed ID: 16389067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study.
    Castaño G; Mas R; Fernández L; Illnait J; Gámez R; Alvarez E
    Int J Clin Pharmacol Res; 2001; 21(1):43-57. PubMed ID: 11708574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia.
    Series JJ; Gaw A; Kilday C; Bedford DK; Lorimer AR; Packard CJ; Shepherd J
    Br J Clin Pharmacol; 1990 Jul; 30(1):49-54. PubMed ID: 2390432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of bezafibrate on lipoprotein lipids and apolipoproteins B and A1 in patients with primary hypercholesterolemia].
    Branchi A; Sommariva D; Tirrito M; Bonfiglioli D; Pini C; Scandiani L; Orlandi S; Fasoli A
    Clin Ter; 1987 Jul; 122(1):17-23. PubMed ID: 2973892
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial.
    Hummel J; Westphal S; Weber-Hamann B; Gilles M; Lederbogen F; Angermeier T; Luley C; Deuschle M; Kopf D
    J Clin Psychiatry; 2011 Jul; 72(7):885-91. PubMed ID: 21294998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
    Bays H; Giezek H; McKenney JM; O'Neill EA; Tershakovec AM
    Metab Syndr Relat Disord; 2012 Aug; 10(4):260-6. PubMed ID: 22400810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use.
    Crepaldi G; Fellin R; Calabrò A; Rossi A; Ventura A; Mannarino E; Senin U; Ciuffetti G; Descovich GC; Gaddi A
    Atherosclerosis; 1990 Apr; 81(3):233-43. PubMed ID: 2190565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia.
    Davidson MH; Donovan JM; Misir S; Jones MR
    Am J Cardiovasc Drugs; 2010; 10(5):305-14. PubMed ID: 20860413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
    Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
    Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
    Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
    Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.